© BusinessWire
28.01.2026
PAHC
LISTED
NASDAQ
Phibro Animal Health Corporation to Host Webcast and Conference Call on Second Quarter Results
News Preview
Phibro Animal Health Corporation (Nasdaq: PAHC) expects to announce its second quarter financial results on Wednesday, February 4, 2026, after the market closes. Phibro management will host a conference call and webcast on Thursday, February 5, 2026, at 9:00 AM Eastern Time.
Interested parties are invited to listen to the conference call and vie...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CON
LISTED
NASDAQ
Concentra Announces Preliminary 2025 Financial Results, Provides 2026 Financial Guidance, and Announces Q4 2025 Earnings Call Date
News Preview
Concentra Group Holdings Parent, Inc. (“Concentra,” the “Company,” “we,” “us,” or “our”) (NYSE: CON), the nation’s largest provider of occupational health services by number of locations, today released preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025, exceeding its previously issued guidance for...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CTNM
LISTED
NASDAQ
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
News Preview
Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated therapies for the treatment of neuroscience, inflammation and immunology (NI&I) indications, today announced that on January 26, 2026 (Grant Date), the Compensation Committee of the Company’s Board of Dir...
Themefolio
Profiler
Peergroup
Worth to know
20.10.2025
Short Selling Radar
USA, Europe, Asia
Track Short Selling Activities worldwide
Knowing what matters
Short sale statistics, hedge fund activities and much more user-friendly information
© BusinessWire
28.01.2026
CNMD
LISTED
NYSE
CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
News Preview
CONMED Corporation (NYSE: CNMD) today announced financial results for the fourth quarter and full-year ended December 31, 2025.
Fourth Quarter 2025 Highlights
Sales of $373.2 million increased 7.9% year-over-year as reported and 7.1% in constant currency.
Domestic revenue increased 1.4% year-over-year.
International revenue increased 17...
Themefolio
Profiler
Peergroup
Swarmalpha i/o · The Event Futures Prediction X
23.01.2026
© BusinessWire
28.01.2026
GDRX
LISTED
NASDAQ
GoodRx Announces Date for Fourth Quarter and Full Year 2025 Earnings Release and Conference Call
News Preview
GoodRx Holdings, Inc. (Nasdaq: GDRX) (“GoodRx” or the “Company”), the leading platform for prescription savings in the U.S., today announced it will release its fourth quarter and full year 2025 financial results after U.S. markets close on Wednesday, February 25, 2026. GoodRx management will also hold a conference call and webcast the following m...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
CRTX
LISTED
NASDAQ
Quince Therapeutics Presents Safety Data from Long-Term eDSP Treatment in Children with Ataxia-Telangiectasia at British Paediatric Neurology Association Annual Meeting
News Preview
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of previously published safety data from the long-term treatment of children with Ataxia-Telangiectasia (A-T) at the British Paediatric...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
PSNL
LISTED
NASDAQ
Personalis to Participate in the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, announced today that its management team will be attending the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Wednesday, February 11, 2026 at the Cliff Lodge in Snowbird, UT.
About Personalis, Inc.
At Personalis,...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
STE
LISTED
NYSE
STERIS Announces Dividend of $0.63 per share
News Preview
DUBLIN, IRELAND, Jan. 28, 2026 (GLOBE NEWSWIRE) -- STERIS plc (NYSE: STE) (“STERIS” or the “Company”) announced today that the Company will distribute a quarterly dividend of $0.63 per share. The dividend is payable on March 19, 2026, to shareholders of record at the close of business on February 17, 2026. ...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AGE
LISTED
XASE
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson’s disease
News Preview
- Phase 1b clinical site start-up and regulatory activities in Australia underway to support the global registrational program -...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SENS
LISTED
XASE
Senseonics Holdings, Inc. to Participate at the BTIG 13th Annual MedTech, Digital Health, Life Science & Diagnostic Tools Conference
News Preview
GERMANTOWN, Md., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development and manufacturing of long-term, implantable continuous glucose monitoring (CGM) systems for people with diabetes, today announced that management will participate in the BTIG 13th Annual MedTech, Dig...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AMRX
LISTED
NASDAQ
Amneal Pharmaceuticals Added to S&P SmallCap 600® Index
News Preview
BRIDGEWATER, N.J., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (Nasdaq: AMRX) (“Amneal” or the “Company”) today announced that it has been added to the S&P SmallCap 600® Index. The inclusion will become effective prior to the opening of trading on Friday, January 30, 2026....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
CBUS
LISTED
NASDAQ
Cibus, Inc. Announces Proposed Public Offering of Class A Common Stock
News Preview
SAN DIEGO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS) (the “Company” or “Cibus”), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that it intends to offer shares of its Class A common stock, par value $0.0001 per share (“Class A Common Stock”), in an underwritt...
Themefolio
Profiler
Peergroup
Advertisment
20.10.2025
© Globe Newswire
28.01.2026
NRIX
LISTED
NASDAQ
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update
News Preview
First patients dosed in DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
OGN
LISTED
NYSE
Organon Completes Divestiture of JADA® System to Laborie
News Preview
Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp. Please see our prior announcement for a summary of the transaction terms.
Indications for Use
The JA...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
GBT
LISTED
EURONEXT
Guerbet: Karim Boussebaa appointed Chief Executive Officer
News Preview
Karim Boussebaa Appointed Chief Executive Officer of Guerbet...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
SNOA
LISTED
NASDAQ
Sonoma Pharmaceuticals Welcomes New Member of its Board of Directors and New Senior Vice President of Regulatory, Quality and Product Development
News Preview
BOULDER, CO / ACCESS Newswire / January 28, 2026 / Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a global healthcare leader developing and producing patented Microcyn® technology based stabilized hypochlorous acid (HOCl) products for a wide range of applications, including wound care, eye care, dermatological conditions, podiatry, and animal hea...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
NHI
LISTED
NYSE
NHI Announces Fourth Quarter 2025 Earnings Release and Conference Call Dates
News Preview
MURFREESBORO, TN / ACCESS Newswire / January 28, 2026 / National Health Investors, Inc. (NYSE:NHI) announced details for the release of its results for the fourth quarter ended December 31, 2025. NHI plans to issue its earnings release after the market closes on Thursday, February 26, 2026, and will host a conference call on the following day, Frid...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
KDEV
LISTED
STO
Karolinska Development AB (publ) announces the outcome of the rights issue and change of the company name to KDventures AB
News Preview
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, CANADA, JAPAN, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH KOREA, SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL. THIS PRESS RELEASE DOES NOT CONSTITUTE AN OFFER...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
VYND
LISTED
OTC
Vynleads Unveils “Done With” Lifestyle Blueprint™ Technology Platform; Readies App Launch
News Preview
Vynleads (OTCQB: VYND), a next-gen technology wellness company pioneering lifestyle-first programs for chronic, behavior-linked conditions, today introduced Done With (DWX), a scalable platform vision built to bring structure to the daily realities of chronic, habit-influenced conditions. DWX is designed to replace overwhelm with clarity through c...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
GDTC
LISTED
NASDAQ
CytoMed Therapeutics Refutes Misleading Claims and Reaffirms Clinical Progress
News Preview
SINGAPORE, Jan. 28, 2026 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, inc...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
DTC
LISTED
CSE
Defence Therapeutics Expands Collaboration with Canadian Nuclear Laboratories to Accelerate Its Proprietary Radiopharmaceutical Pipeline
News Preview
Montreal, Quebec--(Newsfile Corp. - January 28, 2026) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTCQB: DTCFF) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular drug-delivery company, today announced the strengthening of its long-standing collaboration with Canadian Nuclear Laboratories ("CNL") as par...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
CPH
LISTED
TSX
Cipher Pharmaceuticals Announces Health Canada's Acceptance for Review of New Drug Submission for Natroba™ (Spinosad)
News Preview
MISSISSAUGA, ON, Jan. 28, 2026 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") today announced that Health Canada has accepted for review Cipher's new drug submission ("NDS") for Natroba™ (Spinosad), for the treatment of head lice and scabies.
Natroba™ (Spinosad) is widely recognized as one of the most eff...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
ABBV
LISTED
EURONEXT
Allergan Aesthetics Unveils New Data Across Facial Injectables On-Market and Emerging Portfolio at IMCAS 2026 Showcasing Enduring Strength in Advancing Aesthetics Medicine
News Preview
- Nine e-posters presenting comprehensive Allergan Aesthetics portfolio data spanning first-in-class botulinum neurotoxin serotype E (TrenibotulinumtoxinE, "TrenibotE"), onabotulinumtoxinA, hyaluronic acid-based fillers and an innovative filler with biostimulatory properties- Pooled Phase 3 efficacy, safety and patient satisfaction data for Tren...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
MDLN
LISTED
NASDAQ
Medline to report fourth quarter and full year 2025 results on February 25, 2026
News Preview
NORTHFIELD, Ill., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report fourth quarter and full year 2025 financial results on Wednesday, February 25, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference c...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
IZO
LISTED
CSE
Izotropic Provides Corporate Update & Announces Non-Brokered Private Placement
News Preview
Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - January 28, 2026) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3) ("Izotropic", or the "Company"), a medical device company commercializing innovative, emerging technologies and imaging-based products for the more accurate screening, diagnoses, and treatment of b...
Themefolio
Profiler
Peergroup
© Newsfile
28.01.2026
HRAL
LISTED
OTC
Hear At Last Holdings Inc (HRAL) and GG&C Collaborate to Present New Housing Model to Jamaican Government
News Preview
Miami, Florida--(Newsfile Corp. - January 28, 2026) - Hear At Last (OTCID: HRAL) on January 27/26 in collaboration with GG&C, is proud to announce the successful delivery of a comprehensive housing model for presentation to the Jamaican Government. This innovative model is designed to provide a framework for addressing the nation's housing need...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
NTRA
LISTED
NASDAQ
Natera Announces Completion of Enrollment in Randomized ACES-EMB Trial in Heart Transplantation
News Preview
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera’s Prospera Heart test can replace routine invasive biopsies for rejection monitoring in heart transplant recipients.
Positive results would...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
SPRB
LISTED
OTC
Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™
News Preview
Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need, today announced that data on the long-term administration of its tralesinidase alfa enzyme replacement therapy (TA-ERT) for the treatment of Sanfil...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
ENVB
LISTED
NASDAQ
Enveric Biosciences Announces $1.5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
News Preview
Enveric Biosciences, Inc. (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today announced that it has entered into definitive agreements for the purchase and sale of 328,802 shares of common stock at a purchase price o...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
MCK
LISTED
NYSE
McKesson Corporation Declares Quarterly Dividend
News Preview
The Board of Directors of McKesson Corporation (NYSE: MCK) yesterday declared a regular dividend of 82 cents per share of common stock. The dividend will be payable on April 1, 2026, to shareholders of record on March 2, 2026.
About McKesson Corporation
McKesson Corporation is a diversified healthcare services leader dedicated to advancing hea...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
WWH
LISTED
LSE
Worldwide Healthcare Trust PLC - Net Asset Value(s)
News Preview
WORLDWIDE HEALTHCARE TRUST PLC
LEI: 5493003YBCY4W1IMJU04
NET ASSET VALUE
The estimated un-audited net asset val...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
RGNX
LISTED
NASDAQ
REGENXBIO Announces Regulatory Update on Ultra Rare MPS Programs
News Preview
ROCKVILLE, Md., Jan. 28, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced that the U.S. Food and Drug Administration (FDA) placed a clinical hold on its investigational gene therapy, RGX-111, for the treatment of MPS I, also known as Hurler syndrome, following preliminary analysis of a single case of neoplasm (intraventricular CN...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ODYS
LISTED
NASDAQ
Odysight.ai Receives Two Pilot Orders from a Major Defense Customer
News Preview
OMER, Israel, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Odysight.ai Inc. (NASDAQ: ODYS), a developer of AI-based monitoring and Predictive Maintenance solutions, announced today that it has received two pilot orders from a major defense customer for monitoring applications on aerial platforms....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
AIAI
LISTED
CSE
NetraMark Closes First Tranche of Private Placement
News Preview
TORONTO, Jan. 28, 2026 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0), a premier artificial intelligence (AI) company transforming clinical trials with AI-powered precision analytics in the pharmaceutical industry, today announced that further to its press release on January...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SXTP
LISTED
NASDAQ
60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use
News Preview
60 Degrees Pharma licenses FSU technology to purify castanospermine and begins U.S. regulatory steps for non-Rx Australian Chestnut Extract....
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
207940
LISTED
KOE
Samsung Biologics receives EcoVadis Platinum, the highest sustainability rating
News Preview
Ranked in the top one percent among more than 150,000 companies assessed globallyRecognized for strengthened sustainability management across all four assessment categoriesINCHEON, South Korea, Jan. 28, 2026 /PRNewswire/ -- Samsung Biologics (KRX: 207940.KS), a leading contract development and manufacturing organization (CDMO), announced that it h...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
INSM
LISTED
NASDAQ
Insmed to Present Multiple Abstracts on Treprostinil Palmitil Inhalation Powder (TPIP) at Pulmonary Vascular Research Institute (PVRI) 2026 Congress
News Preview
—Abstracts Include the Phase 3 PALM-PAH Study Design, a Presentation of the Previously Disclosed Topline Phase 2b PAH Data, a Functional Respiratory Imaging Analysis from the Phase 2b Study in Pulmonary Arterial Hypertension (PAH), and Pulmonary Vasodilation Data in Rat Models—BRIDGEWATER, N.J., Jan. 28, 2026 /PRNewswire/ -- Insmed Incorporated (N...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
LSL
LISTED
TSX
LSL PHARMA GROUP SUCCESSFULLY OBTAINED U.S. FDA CERTIFICATION FOR THE MANUFACTURING OF OPHTHALMIC OINTMENTS FOR COMMERCIALIZATION IN THE UNITED STATES
News Preview
Approval enables access to the U.S. market and supports future growth opportunitiesBOUCHERVILLE, QC, Jan. 28, 2026 /CNW/ - LSL PHARMA GROUP INC. (TSXV: LSL) (The "Corporation" or "LSL Pharma"), a Canadian integrated pharmaceutical company, is pleased to announce that it has secured certification from the U.S. Food and Drug Administration (FDA) for...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
CALC
LISTED
NASDAQ
CalciMedica Announces Discontinuation of Phase 2 KOURAGE Trial in AKI Following Independent Data Monitoring Committee Recommendation
News Preview
Safety concern warrants reevaluation of study design, including enrollment criteriaPotential future trial with Auxora™ in AKI to be evaluated after data analysisLA JOLLA, Calif., Jan. 28, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company developing novel calcium releas...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
ITGR
LISTED
NYSE
Integer to Highlight Integrated R&D Solutions and Expanded Coating Capabilities During MD&M West 2026
News Preview
Attendees Invited to Experience Integer’s New Booth #3201 Attendees Invited to Experience Integer’s New Booth #3201...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BNTX
LISTED
NASDAQ
BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
News Preview
BioNTech appoints Kylie Jimenez as CPO, effective March 1, 2026, to drive global people strategy supporting its 2030 multi-product oncology vision....
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
GKOS
LISTED
NYSE
Glaukos Announces US FDA Approval of NDA Supplement Allowing for Re-Administration of iDose® TR
News Preview
Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved an NDA labeling supplement allowing for re-administration of iDose® TR using a repeat...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
OKYO
LISTED
LSE
OKYO Pharma Announces Successful Type C Meeting with the FDA
News Preview
FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach FDA confirms Phase 2b/3 clinical design, including primary endpoint, sample size and development approach...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
HALO
LISTED
NASDAQ
Halozyme Raises 2025 Revenue Estimates, Raises 2026 and Multi-Year Financial Guidance
News Preview
Updates Preliminary Unaudited 2025 Estimates:- Total Revenue of $1,385 - $1,400 million, YoY Growth of 36% to 38%1- Royalty Revenue of $865 - $870 million, YoY Growth of 51% to 52%1Raises 2026 Financial Guidance Ranges: - Increases Total Revenue to $1,710 - $1,810 million, YoY Growth of 23% to 30%2 - Increases Royalty Revenue to $1,130 - $1,170 mi...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
TECH
LISTED
NASDAQ
Bio-Techne Launches Simple Plex Ultra-Sensitive Assays on Ella Platform to Enable Femtogram-Level Detection of Neurological Biomarkers
News Preview
Detects low-abundance proteins in blood at femtogram concentrations for earlier disease insightsSupports research in Alzheimer's, ALS, MS, Parkinson's Disease, and Traumatic Brain Injury with validated biomarkersAutomated immunoassay workflow reduces variability; total runtime is under three hoursMINNEAPOLIS, Jan. 28, 2026 /PRNewswire/ -- Bio-Tech...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
VERA
LISTED
NASDAQ
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer
News Preview
Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BIIB
LISTED
NASDAQ
Biogen’s Litifilimab Receives FDA Breakthrough Therapy Designation for Cutaneous Lupus Erythematosus, a Disease With No Targeted Treatment Options
News Preview
CAMBRIDGE, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for litifilimab (BIIB059) for the treatment of cutaneous lupus erythematosus (CLE). Litifilimab is a first in-class, humanized IgG1 monoclonal antibody (mAb)...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
BCT
LISTED
TSX
BriaCell Patients’ Images Show Regression and Resolution of Metastasized Tumors and Immune Activation
News Preview
PHILADELPHIA and VANCOUVER, British Columbia, Jan. 28, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW, BCTXZ, BCTXL) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company developing novel immunotherapies to transform cancer care, releases new images highlighting resolution of metastatic breast...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
DHR
LISTED
NYSE
Danaher Reports Fourth Quarter and Full Year 2025 Results
News Preview
WASHINGTON, Jan. 28, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) (the "Company") today announced results for the fourth quarter and full year 2025. All results in this release reflect only continuing operations and period-to-period comparisons are year-over-year unless otherwise noted.
Key Fourth Quarter 2025 ResultsNet earnings were $1....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
RANI
LISTED
NASDAQ
Rani Therapeutics Announces the Promotion of Alireza Javadi, Ph.D. to Chief Technical Officer
News Preview
SAN JOSE, Calif., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics and drugs, today announced the promotion of Alireza Javadi, Ph.D., to Chief Technical Officer....
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
VREO
LISTED
CSE
Vireo Growth Inc. Enters into Non-Binding Memorandum of Understanding to Acquire The Hawthorne Gardening Company from ScottsMiracle-Gro
News Preview
Planned share-based transaction is expected to be completed during the first fiscal quarter of 2026...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
INDV
LISTED
NASDAQ
Indivior to Report Fourth Quarter and Full-Year 2025 Financial Results and Host Webcast on February 26ᵗʰ
News Preview
RICHMOND, Va., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Indivior Pharmaceuticals, Inc. (Nasdaq: INDV) today announced that it will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026, at 7:00 a.m. U.S. EST. Following the release of the financial results, Joe Ciaffoni, Chief Executive Officer, and other members o...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
TEVA
LISTED
TLV
Teva Innovative Portfolio and Consistent Execution of Pivot to Growth Strategy Deliver Third Consecutive Year of Growth; Pipeline Positioned to Unlock Significant Value Potential
News Preview
Q4 and FY 2025 Highlights:...
Themefolio
Profiler
Peergroup
© BusinessWire
28.01.2026
ANTM
LISTED
NYSE
Elevance Health Reports Fourth Quarter and Full Year 2025 Results; Sets Full Year 2026 Outlook
News Preview
Elevance Health, Inc. (NYSE: ELV) reported fourth quarter and full year 2025 results.
"Elevance Health delivered fourth quarter results in line with our outlook, reflecting disciplined execution in a dynamic environment. As we enter 2026, our focus is on advancing affordability and making healthcare easier to access and navigate for the members...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
2096
LISTED
XETRA
Boehringer Ingelheim und Simcere gehen Partnerschaft ein, um eine dual-zielgerichtete Antikörperbehandlung zur Behandlung von entzündlichen Darmerkrankungen voranzutreiben
News Preview
Neuartiger bispezifischer Antikörper TL1A/IL23p19 zielt auf die Auslöser der Krankheitspathogenese ab, um die Wirksamkeitsgrenze bei entzündlichen Darmerkrankungen zu überwinden. Lizenz- und Kooperationsvereinbarung stärkt Boehringers Pipeline für Entzündungskrankheiten mit einem potenziellen, erstklassigen, präklinischen Wirkstoff.Boehringer erhä...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
JUNS
LISTED
NASDAQ
Jupiter Neurosciences Expands Nugevia™ Addressable Market with Focus on GLP-1 Users
News Preview
Nugevia™ supports metabolic, mitochondrial, and neuroinflammatory biology impacted by GLP-1-driven weight loss...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
SAILIFE
LISTED
BSE
Mabtech and Sai Life Sciences Announce Strategic Collaboration to Advance Immunology Research with EYRA Platform at Sai Boston Site
News Preview
BOSTON and STOCKHOLM, Jan. 28, 2026 (GLOBE NEWSWIRE) -- Mabtech, a global life science tools company specializing in advanced immunoassays, and Sai Life Sciences, a leading integrated Contract Research, Development, and Manufacturing Organization (CRDMO), today announced a strategic collaboration that establishes Sai’s Boston laboratory as a co-m...
Themefolio
Profiler
Peergroup
© Globe Newswire
28.01.2026
DXSP
LISTED
AQXE
DXS International plc (AQSE: DXSP): Half-year Financial Report
News Preview
DXS INTERNATIONAL PLC...
Themefolio
Profiler
Peergroup
© ACCESS Newswire
28.01.2026
MDCE
LISTED
OTC
Medical Care Technologies Inc. (OTC PINK:MDCE) Highlights Melanoma Detection App Development, AI Lifestyle App Launch, and Subsidiary Momentum
News Preview
MESA, ARIZONA / ACCESS Newswire / January 28, 2026 / Medical Care Technologies Inc. (OTC PINK:MDCE) ("MDCE" or the "Company"), a developer of innovative healthcare, lifestyle, and technology-driven solutions, today provided a comprehensive update to shareholders outlining significant progress across its core initiatives and subs...
Themefolio
Profiler
Peergroup
© PR Newswire
28.01.2026
GBT
LISTED
EURONEXT
Neue Indikation bei Kindern ab Geburt für Guerbets halbe Dosis GBCA, Elucirem™ (Gadopiclenol), von der Europäischen Kommission zugelassen
News Preview
VILLEPINTE, Frankreich, 28. Januar 2026 /PRNewswire/ -- Guerbet (FR0000032526 GBT), ein weltweit tätiger Spezialist für Kontrastmittel und Lösungen für die medizinische Bildgebung, freut sich, die Zulassung einer neuen Indikation für sein makrozyklisches Gadolinium-basiertes Kontrastmittel Elucirem™ (Gadopiclenol) bei Kindern ab der Geburt durch d...
Themefolio
Profiler
Peergroup
Long/Short | Fractionals | Margin | Hedge · 4 powerful Trading App | MT4.MT5.ACTIVTRADER | TradingViewplus
More information, click here
More sector specific news
Your Press Release is missing or you want share news over GICS11? Drop us a line.
